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STANDARDIZATION AND VALIDATION OF A
WESTERN BLOT FOR THE DIAGNOSIS OF HUMAN
IMMUNODEFICIENCY VIRUS
ESTANDARIZACIÓN Y VALIDACIÓN DE UN WESTERN BLOT PARA EL DIAGNÓSTICO DEL VIRUS DE
INMUNODEFICIENCIA HUMANA
Eduardo Miranda-Ulloa1,a, Soledad Romero-Ruiz1,b, Bernardina Amorín-Uscata2,c,
Kevin Serrano-Segura1,b, Ronal Briceño-Espinoza1,d, Fany Cárdenas-Bustamante1,b

ABSTRACT
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PAPER
ORIGINAL PAPER

Objectives: To standardize and validate a western blot test for the diagnosis of human immunodeficiency
virus. Methods: A prospective observational study was carried out during 2017 and 2018. The western blot
test was standardized, using the polyacrylamide gel electrophoresis technique with sodium dodecyl sulfate
(SDS PAGE), being the nitrocellulose blot strips prepared with an Optimal HIV-1 antigen concentration of 2.71
µg / mm. The western blot was validated in the laboratory against 400 reference samples (300 sera and 100
plasmas): 200 positive and 200 negatives for antibodies against HIV-1, being the reference test the Immunoblot
of the Fujirebio brand. Diagnostic performance parameters were estimated using Epidat v3.1 and Excel.
Results: Eight important bands of the HIV-1 antigen were identified: p17, p24, p31, p39, gp41, p55, p66, and
gp120. According to the Consortium for the normalization of serology for retroviruse, those that were taken
as specific diagnostic bands were: p24, p31, gp41, and gp120. The sensitivity, specificity, positive and negative
predictive value and validity index against sera were: 96.7%, 96.0%, 96.0%, 96.6%, 96.3%; and against plasmas:
98.0%, 100.0%, 100.0%, 98.0%, 99.0% respectively. No false positives and negatives were found, but some
were undetermined. Conclusions: The development of this western blot test with proprietary technology
presented similar diagnostic performance to the reference test, without showing cross-reactions, being useful
for confirming HIV.
Key words: Western Blotting; HIV; Diagnosis; Sensitivity and Specificity (source: MeSH NLM).

RESUMEN

Ojetivos: Estandarizar y validar una prueba de western blot para el diagnóstico del virus de inmunodeficiencia
humana. Métodos: Se realizó un estudio observacional prospectivo durante el 2017 y 2018. Se estandarizó la
prueba de western blot, usando la técnica de electroforesis en gel de poliacrilamida con dodecil sulfato de
sodio (SDS PAGE), siendo las tiras blot de nitrocelulosa preparadas con una concentración óptima de antígeno
de VIH-1 de 2,71 µg/mm. Se validó el western blot en laboratorio, frente a 400 muestras referentes (300 sueros
y 100 plasmas): 200 positivas y 200 negativas a anticuerpos contra VIH-1, siendo la prueba de referencia el
Inmunoblot de la marca Fujirebio. Se estimaron los parámetros de rendimiento diagnóstico usando el
programa Epidat v3.1 y Excel. Resultados: Se logró identificar ocho bandas importantes del antígeno de VIH1: p17, p24, p31, p39, gp41, p55, p66 y gp120. De ellas, las que se tomaron como bandas diagnósticas específicas
según el Consorcio de normalización de serología para los retrovirus, fueron: p24, p31, gp41 y gp120. La
sensibilidad, especificidad, valor predictivo positivo y negativo e índice de validez frente a sueros fueron:
96,7%, 96,0%, 96,0%, 96,6%, 96,3%; y frente a plasmas: 98,0%, 100,0%, 100,0%, 98,0%, 99,0% respectivamente.
No se encontraron falsos positivos y negativos, pero si algunos indeterminados. Conclusión: El desarrollo
de esta prueba western blot con tecnología propia, presentó similar rendimiento diagnóstico a la prueba de
referencia, sin mostrar reacciones cruzadas; siendo útil para la confirmación del VIH.
Palabras clave: Western blot; VIH; Diagnóstico; Sensibilidad y Especificidad (fuente: DeCS BIREME).
Laboratorio de Referencia Nacional Virus de Transmisión Sexual VIH/SIDA, Centro Nacional de Salud Pública, Instituto Nacional de Salud. Lima, Perú.
Instituto de Medicina Tropical de São Paulo, São Paulo, Brasil.
a
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INTRODUCTION
In Peru, within the strategies for the approach
to infection by the human immunodeficiency
virus (HIV) is the coverage of the diagnosis(1), so
much so that there are serological screening tests
(ELISA, chemiluminescence and rapid tests) and
confirmation: indirect immunofluorescence (IIF) and
immunoblot (IB) or western blot (WB)(2,3). The IIF is a
test with its technology(4), relatively inexpensive and
constitutes 95% of the confirmations at the national
level, however when the result is indeterminate or
nonspecific, the IB or WB is used for having superior
diagnostic performance(3).

Trademarks available from WB include MP
Diagnostics HIV BLOT 2.2 (sensitivity: 100.0%;
specificity: 91.9%)(11), Biorad NEW LAV-BLOT I
(sensitivity: 87.0%; specificity: 99 , 5%)(12) and Biokit
bioblot HIV-1 Plus (sensitivity: 100.0%; specificity:
91.9%)(13). Although these three brands do not
report false positive and negative results (only
indeterminate), their use is very limited due to the
expensive prices attributed to their kits (1,000 to
1,200 dollars for 18 determinations)(11-13).
The western blot, immunoblot, or immunoblotting
is a useful test in identifying antibodies against
HIV. It consists of separating the viral antigens
by electrophoresis in polyacrylamide gels, then
transferred to a nitrocellulose membrane, which
will be subsequently exposed with the antibodies of
the serum or problem plasma. When they come into
contact with an anti-immunoglobulin labeled with
an enzyme, they will react immunologically, giving
rise to a pattern of bands, which will be interpreted
under some of the criteria described by international
organizations(14).
It should be said that, in Peru, around 1,200 annual
samples are resolved by immunoblot/western
blot(15), whose expenses reach more than 60,000
dollars per year. Therefore, due to the need for a
low-cost western blot with our technology and the
high prices of commercial kits, we set ourselves
the following objective: Standardize and validate a
https://inicib.urp.edu.pe/rfmh/vol21/iss4/2
DOI: https://doi.org/10.25176/RFMH.v21i4.4023

METHODS
Design and study area
Prospective observational study of standardization
and validation of a diagnostic test carried out during
2017 and 2018 at the National Institute of Health
(INS) of Peru. Under this approach, the design is
appropriate to estimate the capacity of a measure
that allows discriminating between people with the
disease and without the disease.

Population and sample
The population consisted of sera and plasmas
that belonged to the serum and plasma library
of the National Reference Laboratory of STV-HIV
/ AIDS of the INS during the years 2016 and 2017.
The estimation of the sample size was defined by
convenience, using a non-probabilistic sampling,
with 400 reference samples: 150 HIV-1 positive sera;
150 HIV-1 negative sera (30 from healthy individuals
and 120 from individuals with the following
conditions: twenty with syphilis, twenty from
pregnant women, twenty with rheumatoid disease
(RD), twenty with hepatitis B, twenty with HTLV-1, ten
with cytomegalovirus and ten with dengue); 50 HIV1 positive and 50 negative plasmas. The Reference or
Gold Standard test was the commercial IB (INNO-LIA
™ * HIV I / II Score; Fujirebio, Belgium)(5).

ORIGINAL PAPER

The commercial IB of the Fujirebio brand INNO-LIA
HIV I / II Score (Online Immunoassay: sensitivity
100.0% and specificity 96.7%) is the kit most used
as a second opinion test for samples that did not
resolve IIF(5), being at the same time applied in
numerous studies as a gold standard(6-10), but its main
disadvantage is that its costs are high, approximately
$800 for 20 determinations(5).

western blot to diagnose human immunodeficiency
virus.

Variables and instruments
The standardization and validation of a diagnostic
test implied considering the following variables:
Sensitivity, Specificity, Validity Index, Positive
Predictive Value (PPV), Negative Predictive Value
(NPV), Youden Index, and Negative Likelihood Ratio.
Three stages were previously carried out to measure
these variables.
Optimization in the preparation of the HIV-1
antigen. - The cell cultures of the H9 / HTLV-IIIB line
infected with HIV-1 were prepared, following the
methodology described by Romero -Ruiz et al. (16).
The cell supernatant was washed and centrifuged
three times with 0.9% physiological saline solution
(SSF) at 4,400 rpm for 15 minutes at 2 to 8 ° C. The
sediment or pellet was then resuspended with SSF.
A sonicator was used to carry out the viral and cell
lysis at 6 periods of 60 decibels with 2 minutes per
period and one minute of rest between periods,
maintaining the cold chain (2 to 8 ° C).
Pág. 675
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The sonicated product was centrifuged at 1,500 rpm
for 10 minutes, and its supernatant was registered as
HIV-1 antigen. Finally, the Bradford method(17) was
used to quantify the HIV-1 antigen proteins.
Standardization in the preparation of Western
blot strips.- This step was standardized following
electrophoresis methodology in polyacrylamide gels
with sodium dodecyl sulfate (SDS-PAGE)(18). The MiniProtean vertical electrophoresis chamber (Bio-rad)
was used for 1.0 mm gels (gel size: 8.3 by 7.3 cm). The
percentage of acrylamide was optimized to prepare
the resolving gel, establishing two concentrations
(mixed) 9% (3.8 cm) and 15% (2 cm). The antigen
treatment, separation, and electrophoretic transfer
were carried out following the methodology
described by Miranda et al. (19). Finally, the optimal
concentration of the HIV-1 antigen was established
to prepare the WB strips, being 2.71 µg / mm.
Optimization in the Immunoenzymatic reaction of
the Western blot test.- The optimum volume that
was established in all the steps of this stage was 1
mL. The blot strips were incubated for three hours in
PBS / tween-milk (PBS / 0.1M NaCl, 0.05 M Na2 PO4,
pH 7.2; Tween 20 / 0.3% tween 20; milk / 5% milk)
containing the sera or plasmas of the study at a 1/40
dilution. Next, the nitrocellulose strips were washed
five times with PBS / Tween-20 and incubated
for one hour in PBS / tween-milk containing the
conjugate Anti-human IgG linked to a peroxidase, at
a dilution of 1/1000. The strips were again washed
three times with PBS / Tween-20 and twice with
PBS. Bands were developed against a substrate
solution (30% hydrogen peroxide at 1uL / mL and
diaminobenzidine at 0.5 mg / mL in PBS pH 7.2). The
reaction was stopped by washing the strips with
distilled water.
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Procedures
Reading, interpretation, and validation of the
Western blot test.- For the positivity criterion, the
Consortium guidelines for the normalization of
retrovirus serologies (CRSS)(11-14,20) were considered.
POSITIVE: A band of p24 or p31 and an ENV band
(gp41 or gp120). NEGATIVE: No specific viral band
present. UNDETERMINED: Any specific viral band
present, but the pattern does not meet the criteria
for positive. With these criteria, the WB was validated,
performing the readings and interpretations of the
400 reference samples incorporated into the study.

Statistical analysis
The analysis was estimated using a contingency
table, the Epidat v3.1 program, and Excel. The
percentages of Sensitivity, Specificity, Validity Index,
Positive Predictive Value (PPV), Negative Predictive
Value (NPV), Youden Index, and Negative Likelihood
Ratio were reported, considering a 95% confidence
level (95% CI).

Ethical considerations
The Institutional Research Ethics Committee
approved the study protocol of the National Institute
of Health of Peru with the code: OI-022-14 and with
Directorial Resolution N °: 418-2014-DG-OGITT-OPE
/ INS. Likewise, the General Office for Research and
Technology Transfer approved the final report of this
study with MEMORANDUM N ° 027-2019-OGITT /
INS.

RESULTS
Among our findings, we were able to show eight
important bands corresponding to the HIV-1 viral
proteins: p17, p24, p31, p39, gp41, p55, p66, and
gp120. Of these, those that were taken as specific
diagnostic bands according to the CRSS were: p24,
p31, gp41, and gp120 (Figure 1).
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Figure 1. Reactivity pattern of the western blot test for the detection of antibodies: (C +1) HIV positive in

serum; (C-1) HIV negative in serum; (C +2) HIV positive in plasma; (C-2) negative for HIV in plasma.
Among other findings, we highlight that against the
serum samples, there were eleven indeterminate
results (5 from the positive panel and 6 from the
negative panel), and against the plasma samples,

there was an indeterminate from the positive panel.
Said results of the WB test are shown in the flow
diagram of samples incorporated into the study
(Figure 2).

Figure 2. The flow of samples incorporated into the study.
https://inicib.urp.edu.pe/rfmh/vol21/iss4/2
DOI: https://doi.org/10.25176/RFMH.v21i4.4023
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An important highlight of this WB test is that it did
not show false positives and negatives. However,
only some serum samples had indeterminate results:

Miranda E et al

syphilis (2/20), hepatitis B (2/20), ER (1/20), and HTLV1 (1/20) (Table 1).

Table 1. Validation of the Western blot test to detect antibodies against HIV using positive negative and
interfering samples.

Western Bloth VIH
Quantity

True
positives

False
positives

True
negatives

False
negatives

Undetermined

HIV-1

150

145

-

0

0

5

Syphilis

20

-

0

18

-

2

Pregnant

20

-

0

20

-

0

ER*

20

-

0

19

-

1

Hepatitis B

20

-

0

18

-

2

HTLV-1

20

-

0

19

-

1

CMV**

10

-

0

10

-

0

Dengue

10

-

0

10

-

0

Healthy

30

-

0

30

-

0

HIV-1

50

49

-

0

0

1

HIV-1 negative

50

-

0

50

-

0

Total

400

194

0

194

-

12

Condition

ORIGINAL PAPER

Serums

Plasmas

*ER: Rheumatoid disease. **CMV: Cytomegalovirus

Among the main achievements, we show that the
results of the validation parameters (sensitivity,
specificity, PPV, NPV and Validity Index) for our WB
test were higher than 96.0%. In the same way, the
Youden index with the values of 0.93 and 0.98,
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confirms a minimal possibility of obtaining false
positives or false negatives; as well as a low negative
likelihood ratio of 0.03 and 0.02, which is consistent
with the other results (Table 2).
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Table 2. Parameters of the Western blot test for the detection of antibodies against HIV against serum and
plasma samples

Western Bloth VIH
Serum

Plasma

CI value (95%)

CI value (95%)

Sensitivity (%)

96,7 (93,5 - 99,9)

98,0 (93,1-100,0)

Specificity (%)

96,0 (92,5 - 99,5)

100,0 (99,0 - 100,0)

Validity Index (%)

96,3 (94,0 - 98,6)

99,0 (96,6 - 100,0)

Predictive value + (%)

96,0 (92,6 - 99,5)

100,0 (99,0 - 100,0)

Predictive value - (%)

96,6 (93,4 - 99,9)

98,0 (93,3 - 100,0)

Youden index

0,93 (0,88 - 0,97)

0,98 (0,94 - 1,02)

Likelihood ratio

0,03 (0,01 - 0,08)

0,02 (0,0 - 0,14)

Parameters

ORIGINAL PAPER

IC 95%: Confidence interval at 95%

DISCUSSION
The reference test used in the present study is the
most used in Peru(2,3,6,15), and other countries(5, 7-10), the
insert reports a sensitivity of 100% and specificities of:
96.7% (blood bank) and 96.1% (clinical samples). This
kit incorporates recombinant proteins and synthetic
peptides from HIV-1 and HIV-2(5). The sensitivity and
specificity of our WB using antigenic proteins from
HIV-1 lysis were higher than 96.0%; even so, we did
not have false negatives and positives, which allows
us to deduce that our results for the same parameters
are similar.
Western blot kits NEW LAV BLOT I (Biorad)(12) and
bioblot HIV-1 plus (Biokit)(13) using the CRSS positivity
criteria, report sensitivities of 99.5% and 94.9% and
specificities 87.0% and 91.9%, respectively. At the
same time, they report that they did not have false
negatives and positives, only indeterminate(12,13).
Likewise, the Immunoblot Recom Line HIV-1 & HIV-2
IgG kit (Mikrogen diagnostik)(21), reports a sensitivity
of 100% and specificities of: 99.3% (blood bank),
98.5% (samples clinical) and 96.4% (interfering). Our
WB test for the same parameters showed results
comparable to the three western blot / Immunoblot
brands described.
Due to the indeterminate results obtained, a
sensitivity of 100.0% was not achieved; This could be
https://inicib.urp.edu.pe/rfmh/vol21/iss4/2
DOI: https://doi.org/10.25176/RFMH.v21i4.4023

due to the fact that the antibodies against p24 and
p31 decrease during the course in the AIDS phase,
which causes a displacement of the interpretation
from positive to indeterminate(11); however, we do
not know if the samples came from patients in this
phase.
To establish specificity (sera), indeterminate results
represented 4.0% (6/150); It should be said that,
for the calculations in other validation studies,
indeterminates are not considered in the category
of false positives(22), being this way, we would have
a global specificity of 100.0%, in the 144 samples
(144/144). In general, the indeterminate (12/400)
that we obtained (Table 1) does not affect the
diagnostic efficiency of our WB since the Peruvian
technical standard indicates to perform the HIV-1
viral RNA PCR test (viral load) on the indeterminate
or proviral-HIV-1 DNA PCR(2).
Our standardized and validated test followed a WB
design developed for parasites, which had excellent
results in Peru(19,23-25). The different commercial brands
of immunoblot/western blot for HIV use a conjugate
containing the enzyme alkaline phosphatase, the
substrate 5-Bromo-4-chloro-3-indolyl phosphate
(BCIP) and nitro blue tetrazolium(5,11-13,21). While in our
WB we used a conjugate containing peroxidase, the
substrate hydrogen peroxide and diaminobenzidine
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as a chromogen, similar to these reagents they were
used in the WB DAVIH-BLOT kit from Cuba, which
showed good diagnostic performance against
samples serum, urine and oral fluid(26).
In addition, the strip size format and the volume to
be used are similar to the Reference test(5), while the
other commercial brands use larger blot strips and
consequently require double the volume of reagents.
The aforementioned conditions are important to
highlight because our methodology saves, since it
uses fewer reagents. At the same time, we prepare
our viral antigen, having the advantage that the
INS has a Biosafety Level III Laboratory, where it is
performing the maintenance and development of
cell cultures of the H9 / HTLV-IIIB line infected with
HIV-1. Consequently, our WB test would cost up to
ten times less than commercial kits.
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The WB test was standardized and validated in
the laboratory, being a limitation of the study in
completing its validation in the field. It can be
implemented in the reference laboratories of Peru.

CONCLUSION
The results of the parameters obtained in the WB test
for the detection of antibodies against HIV qualify it
as a test of good diagnostic performance and make
it useful for serological confirmation. Consequently,
we recommend its use in the National Reference
Laboratory of the INS Sexually Transmitted Virus Test
as an alternative assay to commercial confirmatory
tests in addition to significantly reducing costs in HIV
confirmation.
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